Cardiovascular safety of ADHD medications: Rationale for and design of an investigator-initiated observational study

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 9, 2010, Pages 934-941

  Hennessy, Sean ^a   Schelleman, Hedi ^a   Daniel, Gregory W ^b   Bilker, Warren B ^a   Kimmel, Stephen E ^a   Guevara, James ^a,c   Cziraky, Mark J ^b   Strom, Brian L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HEALTHCORE INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Amphetamine; Atomoxetine; Cardiovascular adverse event; Methylphenidate; Pharmacoepidemiology

Indexed keywords

AMPHETAMINE DERIVATIVE; ATOMOXETINE; METHYLPHENIDATE;

ADOLESCENT; ADULT; AGED; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DEATH; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; OBSERVATIONAL METHOD; PRIORITY JOURNAL; STROKE; SUDDEN DEATH;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; COHORT STUDIES; DATABASES, FACTUAL; HUMANS; METHYLPHENIDATE; MYOCARDIAL INFARCTION; PROPYLAMINES; RESEARCH DESIGN; UNITED STATES;

EID: 77957357525     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1992     Document Type: Article

References (46)

1. Chavez B, Sopko MA Jr, Ehret MJ, et al. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder. Ann Pharmacother 2009; 43: 1084-1095.
2. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354: 1445-1448.
3. Stowe CD, Gardner SF, Gist CC, Schulz EG, Wells TG. 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother 2002; 36: 1142-1149.
4. Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 919-927.
5. Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006; 21: 92-95.
6. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26: 729-740.
7. Communication about an Ongoing Safety Review of Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder (ADHD) http://www.fda.gov/Drugs/DrugSafety/Postmarket- DrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ ucm165858htm (accessed 2 December 2009).
8. Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2007; 120: e1494-1501.
9. Medicare Payment Advisory Commission. Report to the Congress: New Approaches in Mediciare. 2004.
10. Hennessy S, Leonard CE, Palumbo CM, Newcomb C, Bilker WB. Quality of Medicaid and Medicare data obtained through Centers for Medicare and Medicaid Services (CMS). Med Care 2007; 45: 1216-1220.
11. Willey VJ, Bullano MF, Hauch O, et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 2004; 26: 1149-1159.
12. Bullano MF, Willey V, Hauch O, Wygant G, Spyropoulos AC, Hoffman L. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization. J Manag Care Pharm 2005; 11: 663-673.
13. Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database. Am J Cardiol 2006; 97: 61C-68C.
14. Bullano MF, Kamat S,Willey VJ, Barlas S,Watson DJ, Brenneman SK. Agreement between administrative claims and the medical record in identifying patients with a diagnosis of hypertension. Med Care 2006; 44: 486-490.
15. Kamat SA, Gandhi SK, Davidson M. Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals. Curr Med Res Opin 2007; 23: 1121-1130.
16. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 731-737.
17. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550-560.
18. James A, Lai FH, Dahl C. Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand 2004; 110: 408-415.
19. Hennessy S, Leonard CE, Freeman CP, et al. Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf 2010; 19(6): 555-562.
20. Leibson CL, Naessens JM, Brown RD, Whisnant JP. Accuracy of hospital discharge abstracts for identifying stroke. Stroke 1994; 25: 2348-2355.
21. Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998; 29: 415-421.
22. Rosamond WD, Folsom AR, Chambless LE, et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999; 30: 736-743.
23. Williams GR, Jiang JG, Matchar DB, Samsa GP. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke 1999; 30: 2523-2528.
24. Heckbert SR, Kooperberg C, Safford MM, et al. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol 2004; 160: 1152-1158.
25. Pladevall M, Goff DC, Nichaman MZ, et al. An assessment of the validity of ICD Code 410 to identify hospital admissions for myocardial infarction: the Corpus Christi Heart Project. Int J Epidemiol 1996; 25: 948-952.
26. Petersen LA, Wright S, Normand SL, Daley J. Positive predictive value of the diagnosis of acute myocardial infarction in an administrative database. J Gen Intern Med 1999; 14: 555-558.
27. Tu JV, Naylor CD, Austin P. Temporal changes in the outcomes of acute myocardial infarction in Ontario, 1992-1996. CMAJ 1999; 161: 1257-1261.
28. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004; 148: 99-104.
29. Cox DR. Regression models and life tables. J Roy Statist Soc B 1972; 34: 187-220.
30. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129: 125-137. (Pubitemid 19030705)
31. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923-936.
32. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009; 166: 992-1001.
33. Holick CN, Turnbull BR, Jones ME, Chaudhry S, Bangs ME, Seeger JD, Atomoxetine and. cerebrovascular outcomes in adults. J Clin Psychopharmacol 2009; 29: 453-460.
34. McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf 2009; 32: 1089-1096.
35. Winterstein AG, Gerhard T, Shuster J, Saidi A. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics 2009; 124: e75-80.
36. Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, et al. Utilization of pharmacologic treatment in youths with attention deficit/ hyperactivity disorder in Medicaid database. Ann Pharmacother 2008; 42: 24-31.
37. Driscoll DJ, Edwards WD. Sudden unexpected death in children and adolescents. J Am Coll Cardiol 1985; 5: 118B-121B.
38. Wren C, O'Sullivan JJ, Wright C. Sudden death in children and adolescents. Heart 2000; 83: 410-413.
39. Burke AP, Farb A, Virmani R. Causes of sudden death in athletes. Cardiol Clin 1992; 10: 303-317.
40. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 199. Circulation 2001; 104: 2158-2163.
41. Jordan LC, Hillis AE. Hemorrhagic stroke in children. Pediatr Neurol 2007; 36: 73-80.
42. Petitti DB, Sidney S, Quesenberry CP Jr, Bernstein A. Incidence of stroke and myocardial infarction in women of reproductive age. Stroke 1997; 28: 280-283.
43. Wellenius GA, Schwartz J, Mittleman MA. Air pollution and hospital admissions for ischemic and hemorrhagic stroke among medicare beneficiaries. Stroke 2005; 36: 2549-2553.
44. H-CUPnet. Available at: http://hcupnet.ahrq.gov/ (accessed 1 May 2009).
45. Greenlee RT, Naleway AL, Vidaillet H. Incidence of myocardial infarction in a general population: the Marshfield Epidemiologic Study Area. WMJ 2002; 101: 46-52.
46. Anderson RN, Smith BL. Deaths: Leading causes for 2002 National vital statistics reports; vol 53 no 17 Hyattsville, Maryland: National Center for Health Statistics, 2005.